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ABSTRACT 
Background: In the US, cancer is 2nd leading cause of death in children. Surprisingly, the 
prevailing treatment regimens have been modified from adult therapies. Yet, substantial 
differences exist between adult and pediatric cancers. Determining the underlying genetic causes 
of pediatric cancers is problematic for many reasons, including the overall rarity. In order to gain 
tractability in this disease, we need a new model that closely recapitulates pediatric cancers, but at 
much higher incidence. The pet dog is ideally suited to be this model. 
Significance: Children experience varying degrees of suffering due to the side effects of treatment 
modalities that are primarily non-specific. Isolating genetic causes would allow for personalized 
treatments and increase survival. 
Purpose: The purpose of this work was to identify genetic and epigenetic (DNA methylation) 
biomarkers in an animal model of pediatric lymphoma that are associated cancer survival. 
Conceptual Framework: We used the genetic single gene-two hit model (Hussian, 2015) to 
guide this work. This framework combines rare and common variant theories with the addition 
of mutator/anti-mutator modulation to lead to disease development.  
Methods: Using chemotherapy naive tumor samples from 71 dogs diagnosed with aggressive 
lymphomas, we analyzed gene expression using Affymetrix Genechip 2.0 arrays. Additionally, we 
performed whole genome methylation analysis (MeDIP) on a subset of 6 dogs. Data was 
normalized and analyzed using a genomics statistical suite (JMP). We further validated our 
expression results in an online publically available database of 91 pediatric lymphoma tumors. 
Results: After selecting the significant transcripts (fold-change ≥ 3 and p ≤ 0.001), we correlated 
these in a subset of dogs with survival time. We identified 6 prognostic genes significantly 
associated with cancer survival. In the methylation analysis, we identified 633 differentially 
methylated first exons of genes (p ≤ 0.01). Overlapping both the expression and methylation 
analysis, we identified 1 gene (Cadherin 1, CDH1). The expression of this gene was significantly 
associated with survival in pediatric lymphoma (p = 0.013). 
Conclusions: This study is one of the first to provide genetic understanding of aggressive 
lymphomas that have relevance in children. Focusing on the molecular properties of pediatric 
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AN ANIMAL MODEL OF THE CHILDHOOD LYMPHOMA IMPLICATES 
IMPORTANT PROGNOSTIC GENES IN CANCER SURVIVAL 
 
INTRODUCTION 
In the United States, the leading cause of death by disease after infancy among children 
and adolescents is cancer, with nearly 2,000 dying from the disease in 2017 alone [1]. Yet, survival 
has never been higher, with 89% (~13,000) surviving > 5 years. Due to the growing nature of this 
population, selecting effective, risk‐adapted medical treatment can be very challenging [2]. 
Currently, the majority of existing treatment regimens for pediatric cancers have been modified 
from adult therapies [3]. Within the last decade, the long-term effects of such non-specific 
treatments have been identified [4]. Termed “late effects”, long-term childhood cancer survivors 
experience debilitating physical and psychosocial diseases and symptoms after completion of 
treatment that persists into and throughout adulthood [5-8]. In fact, nearly 90% of childhood cancer 
survivors experience “a lot or a great deal of suffering from at least one symptom” [9, 10]. Despite 
this, the burden of symptom experience during cancer diagnosis, treatment, and follow-up is not 
well managed, notwithstanding considerable research on the long-lasting nature of such symptoms 
and clinical recommendations based on this evidence [11]. Currently, implementation of these 
guidelines and research to understand the complex interaction of systems (physiological, 
psychological, environmental, etc.) that lead to the symptom experience associated with childhood 
cancers is not well elucidated [9, 12, 13]. Cancer is now recognized as a disease of abnormal 
epigenetics, and aberrant DNA methylation patterns have already been associated with some 
childhood cancers [14-16]. Urgently needed are clear genetic/epigenetic treatment targets, which 
are cancer cell-specific and do not have an effect on the rapidly growing tissues in a child. Here, 
we use the pet dog as a model of childhood high-grade (aggressive) lymphomas. We identify the 
PROGNOSTIC GENES IN CANCER SURVIVAL                Sotojima, R. Page 4 of 25 
epigenetic biomarkers in canine lymphoma, associated with survival and cancer development, to 
gain higher understanding of pediatric cancers. The unique aspects of pediatric Diffuse Large B-
Cell Lymphoma (DLBCL) can be used for prevention, diagnosis, treatment, and improvement of 
long-term outcomes for children with DLBCL. Moreover, this genetic knowledge could allow for 
sub-classification of tumors, symptoms, and treatments which may be utilized for translational 
studies in the future. 
BACKGROUND 
Pediatric High-grade Lymphomas 
In children, Lymphoma (Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL)) 
is the third most common 
childhood malignancy [18]. 
NHL is a heterogeneous 
classification of 
malignancies and includes 
more than 70 subtypes [19-
21]. NHL arises from either 
B or T white blood cells 
(lymphocytes) of the immune system at various stages of cell differentiation [22, 23]. Overall, 
NHL accounts for about 5% of all childhood cancers, with approximately 800 new pediatric 
cases diagnosed each year [24-26]. Of those cases, 10-20% will be DLBCL, the most common 
subtype of NHL [27]. Interestingly, various age-related differences in tumor biology and survival 
have been observed suggesting that childhood cancers differ significantly in critical ways from 
adult cancers (Table 1)[28]. 
Table 1: Comparison of DLBCL in Adults, Children, and Dogs. We 
compared adults and children on several cancer related features and find 
adults differ significantly from kids but kids and dogs share features. 
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 For example, one significant difference between pediatric and adult DLBCL is the 
prognosis; while adults who receive multi-agent chemotherapy only has a survival rate of 50%, 
children have the survival rate of 85-95% [27]. Further, differential expression in pediatric and 
adult DLBCL suggest mechanistic reasons for the disparate outcomes [22]. Bcl2 (apoptosis 
regulator gene) is highly expressed in adult DLBCL while children with the disease have a low 
expression [27]. Conversely, pediatric cases demonstrate increased expression of c-Myc (a proto-
oncogene) while adults cases demonstrate low expression [27]. Additionally, extranodal disease is 
more frequent in pediatric cancers, the tumor morphology differs between that of adults and 
children, and in pediatric DLBCL a common translocation in the adult cancer [t(14;18)] is rarely 
observed in the pediatric cases [22, 27].  
Yet, despite the clear differences in the nature of pediatric and adult onset DLBCL, there 
are many aspects of pediatric DLBCL genetics that remain unclear due to the inherent issues 
associated with studying pediatric cancers. For example, while cancer is the 2nd leading cause of 
death in children, incidence of cancer in kids is rare overall, especially given the multiple types of 
cancer that children develop [29]. The most common subtype of NHL only accounts for a total of 
80-160 new diagnoses each year [27]. Thus, dividing pediatric cancers into specific subtypes for 
meaningful clinical intervention results in insufficient sample sizes to power genome-wide 
associations [3]. In order to gain tractability in the genetic causes of pediatric cancers for improved 
specific treatments, an alternative model that very closely recapitulates pediatric cancers at higher 
rates is needed.  
The Pet Dog as a Genetic Model 
The domesticated dog (Canis lupus familiaris) is an excellent model of human cancers for 
several reasons, including their easy accessibility and prominent status in diverse cultures [30]. 
PROGNOSTIC GENES IN CANCER SURVIVAL                Sotojima, R. Page 6 of 25 
For instance, over $40 billion (USD) is spent annually on dog health care [31] which is second 
only to humans in the level of health care received [32]. While laboratory animal models have long 
been used to study many diseases, recently, several studies have claimed that domestic dogs are 
the better animal model for human diseases [33]. This is partly due to dogs sharing over ~650 Mb 
of ancestral sequence with humans that is absent in mice, and them having DNA and protein 
sequence that is more similar to human than it is between human and mouse [26, 27]. Additionally, 
dog and human tumors demonstrate similar histopathology suggesting dogs and humans having 
complementary genetic features [33]. However, the greatest advantage of dog models is the result 
of their evolutionary history that involved at least two severe population bottlenecks [30]. 
Approximately 200 years ago most dog breeds were created by the selection of morphological and 
behavioral traits [34-36]. This was vastly accelerated during the controlled breeding practices of 
the Victorian era (circa 1830–1900), when crosses between breeds from divergent genetic lineages 
become highly desirable [18, 37]. Today’s breeds are essentially isolated genetic populations 
whose genetic similarities and differences can be exploited to identify disease mutations [35].  
Advantageously for any animal model of human diseases, dog cancer rates are very high, 
with NHL accounting for at least 10% of the over 6 million cancer diagnoses made each year [83% 
of all haematopoietic malignancies; 20, 38, 39]. Specifically, in DLBCL the incidence is estimated 
at 20 – 125 /100,000, suggesting national DLBCL rates of ~17,000 – 112,000 dogs [40-42]. The 
incidence of NHL is increasing in both dogs and humans and varies depending on age, histology, 
gender, and race [43]. In both humans and canines, activating pathway processes in 
lymphoproliferative diseases are shared, and evidence suggests that there are similarities in tumor 
microenvironment, clinical, cytological, and immunophenotypic between both species [44, 45]. In 
canines, as in humans, DLBCL is the leading identified histotype (44.4%) and is of primary B-cell 
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origin [31]. A seminal work in this field identified two primary expression patterns in DLBCL – 
this was observed in both humans and canines [32, 44, 46, 47]. And while the two differential 
expression patterns were not 100% concordant in terms of all genes within each group, canine and 
human lymphomas clustered according to subtype, not species [38, 47]. More recently, dogs are 
being used in clinical trials to study NF-kB-targeted therapeutics for human lymphoma due to the 
genetic similarity of the tumors [38]. Collectively, these studies identify molecular similarities in 
human DLBCL that suggest pet dogs are a highly representative model of DLBCL [47, 48].  
Purpose 
1. Identify differential gene expression in high-grade canine lymphoma tumor compared to 
locally adjacent normal tissue with cancer survival. 
2. Identify differential DNA methylation in high-grade canine lymphoma tumors compared 
to locally adjacent normal tissue sample.  
Conceptual Framework 
We used the genetic single gene-two hit model to guide this work [17]. This framework 
combines rare and common variant theories with the addition of mutator/anti-mutator 
modulation to lead to disease development. 
METHODS 
Study Design 
This study was designed to be a cross-sectional gene expression and DNA methylation 
analysis in pet dogs that presented to The Ohio State University Veterinary Medical Center and 
were diagnosed with High-grade B-cell lymphoma (HBL).  
 
 
Sample Collection & Diagnosis 
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Animal care and sample collection were carried out in accordance with all applicable 
institutional, local, and national guidelines; dogs were under the care of licensed veterinarians, and 
participation did not influence decisions of care. Sample collection protocols were approved and 
reviewed by the Institutional Review Board of The Ohio State University and the Institutional 
Animal Care and Use Committee (IACUC) of The Ohio State University. Following an IACUC 
approved protocol, whole blood and tumor samples were collected by a licensed veterinarian or 
veterinary technician from pet dogs brought to The OSU Veterinary Medical Center for clinical 
evaluation. During routine clinical diagnosis, a 7-mL purple-top blood tube was obtained as well 
as tissue following tumor resection for pathology. Tumors were classified according to the 
modified WHO criteria based on morphology and immunophenotyped [49]. Based on the recent 
update of the 4th edition of the World Health Organization Classification of Haematopoietic and 
Lymphatic Tissues, the newly proposed classification of HBL represent more clinically aggressive 
cancer types and are associated with poor outcomes [50, 51]. Using this classification, we collected 
71 high-quality biological samples from dogs diagnosed with three subtypes of canine HBL 
(cHBL): DLBCL (n = 52), Burkitt's-like lymphoma (BKL, n = 14), and Marginal Zone B-cell 
lymphoma (MZL, n = 5). Additionally, dogs diagnosed with Benign Follicular Hyperplasia (n = 
7) after receiving lymph node resection were used as controls. Methodology used for pathology 
classification and diagnosis is standard in the field and has been used previously [52].  
Biological Sample Preparation 
DNA Isolation: Genomic DNA was isolated from leukocytes using 5 Prime ArchivePure 
DNA Blood Kits (Gaithersburg, MD) as per protocol. Samples were tested for quality using a 2% 
pre-stained ethidium bromide agarose gel with electrophoresis and subsequent fluorescence. 
Additional quality control included measurements with the Nanodrop 2000 and Qubit 3.0 
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Fluorometer readings per manufacturer’s protocols. Results demonstrated visualized DNA as 
compact, high-molecular-weight bands with no low-molecular-weight smears and OD260/280 
ratios ≤ 1.8 and OD260/230 ratios ≤ 2.0, thus indicating intact high-quality genomic DNA.  
RNA Isolation: Total RNA was extracted from each tumor and locally adjacent normal 
tissue sample using TRIzol reagent (Invitrogen, San Diego, CA, USA). RNA was isolated from 
biopsy cells recovered from cryopreservation using the RNAeasy Mini Kit and QIAshredder 
(QIAGEN, Valencia, California) [as performed previously in 53]. RNA concentration was 
determined using NanoDrop ND-1000 UV-Vis spectrophotometer (NanoDrop Technologies, 
Wilmington, Delaware), and quality was measured using a 2100 Bioanalyzer (Agilent, Santa Clara, 
California). All the samples included in the gene expression profiling experiment were suitable for 
microarray analysis based on RNA quality (RIN > 7.0). 
Array Hybridization & Sequencing 
Affymetrix GeneChip Genome 2.0 Microarray: Using total RNA (isolation described above) 
from tumor and locally adjacent normal tissue samples, this microarray was processed at The Ohio 
State University Comprehensive Cancer Center Genomics Core (an approved Affymetrix 
laboratory site) for canine gene expression profiling. The array consists of 42,900 probe sets with 
11 probe pairs per gene sequence. Oligonucleotide probe length for each probe is a 25-mer. For C. 
familiaris, there are 18,000 reference sequences, representing 20,000 non-redundant predicted 
genes. The sequence information provided in this array is from public data sources, including 
GenBank, UniGene, mRNAs, and the BROAD-1 annotation dataset. Collected samples were 
prepared following the standard Affymetrix protocol, as indicated by the manufacturer. Samples 
were hybridized to Affymetrix Canine 2.0 gene chips (Affymetrix, Santa Clara, California). 
Approximately 2.5 µg of RNA were labeled using the Affymetrix labeling protocol (Affymetrix, 
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Santa Clara, CA). The cRNA samples were then hybridized to Canine 2 gene expression chips as 
described [54]. The Canine 2.0 gene expression chip contains 43,000 annotated sequences derived 
from the 7.5× canine genome [55]. These represent virtually every known gene and a complement 
of expressed sequence tags that provide strong redundancy for expression profiling.  
MethylCap-seq Library Generation and Sequencing: For DNA methylation analysis, we 
selected MethylCap-seq. This is a cost-efficient, genome-wide, highly reproducible, high-
throughput, less cumbersome method than other traditional techniques used for interrogating 
methylated regions [56-58]. After fragmentation, methylated DNA is captured with the high 
affinity methyl-CpG binding domain of human MBD2 protein and eluted in a step-wise manner 
indicative of methyl-CpG density [57, 58]. Consequent analysis is performed on the enriched 
fragments by massively parallel sequencing [56, 57]. MethylCap-Seq was performed at The Ohio 
State University Comprehensive Cancer Center’s Genomics Shared Resource. Briefly, DNA was 
quantified by Qubit fluorometric quantitation (Life Technologies, Grand Island, NY). 1-1.3 μg 
DNA was subjected to fragmentation using a Covaris S2 Adaptive Acoustic instrument (Woburn, 
MA) to average fragment size of 100 – 250 bp. Methylated DNA enrichment fragments were 
enriched using the Diagenode AutoMethylCap Kit customized for the Diagenode SX-8G IP-Star 
Compact Automated System (Denville, NJ). 1 ng of the resultant enriched and ethanol precipitated 
methylated DNA was used to generate an Illumina-compatible sequencing library using the Kapa 
Hyper Prep Kit (Fremont, CA). Library fragments (average fragment size is 300-400 nt, including 
adapters) were amplified using Phusion High-Fidelity PCR Master Mix with HF Buffer (NEB) for 
8 PCR cycles. Library material was purified with Agencourt AMPure XP beads (1:1 volume; 
Beckman Coulter, Inc., Indianapolis, IN). Sequencing was performed on the Illumina HiSeq 2500 
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(San Diego, CA) using the single-end 50-bp approach (Version 3 chemistry) to a depth of at least 
40 million passed filtered reads. 
MethylCap-seq Read Alignment & Assignment of Methylation Values from Reads: 
Sequencing reads were received in fastq format. Duplicates (i.e. all reads with the same sequence 
data) among passed filter (using default Illumina settings) sequencing reads were collapsed. 
Collapsed reads were quality trimmed using a quality score cutoff of 33 using the fastx toolkit. 
Reads were then aligned to the canine genome CanFam3 using bowtie [version 0.12.7, 43]. DNA 
fragment profiles were extracted for every sample from Bioanalyzer data using a custom python 
script. These fragment profiles and the aligned reads were employed to assign methylation values 
to every CpG in the human genome using PrEMeR-CG [59]. Finally, differential methylation was 
called between Day 1 and Day 3 samples using paired MethMAGE on the first exons of protein 
coding genes [60]. We focused on the methylation of first exons of annotated protein coding genes, 
which has been shown to be especially relevant for regulation of gene expression [61]. Given that 
this is the first genome-wide analysis of canine DNA methylation changes, we applied stringent 
thresholds to the data. We removed any regions in which MethMAGE failed (due to absence of 
methylation data), required that the maximum of the methylation signal in the two groups within 
a region was above its median across all regions, and applied Benjamini Hochberg FDR [BHFDR, 
46] with a q-value cutoff of 0.01.  
Statistical & Laboratory Analysis  
Software: The raw probe level signal intensity data from the Affymetrix array was analyzed 
using JMP Genomics [54]. We performed the Basic Expression Workflow that included 
background adjustment, quantile normalization, and probe-set summarization with Median Polish 
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analysis for pre-processing of the raw data [as recommended by JMP, 55]. Pre-processing was 
divided into two phases: Filtering and Quality Control (QC) per recommended protocol.  
Subsequent to the filtering and QC, a final dataset was analyzed using ~40,000 probes. 
Using the finalized dataset, we conducted an Analysis of Variance (ANOVA) to determine 
statistically significant changes in the probe level signal intensities between genes associated with 
specific subtypes of B-cell lymphoma. We set the categorical variables for different lymphoma 
genes (for Hierarchical Clustering) and days of survival (for Kaplan Meier Analysis). We 
conducted a false discovery rate (FDR; allowing tolerance of a limited number of tests to have a 
Type I error) which was controlled at 0.001 using the Benjamini-Hochberg FDR to obtain p-values. 
Subsequent lists of differentially expressed genes were filtered based on fold change and overall 
p-value (additionally calling overlapping genes in cHBL, DLBCL, and BFH using mean 
expression with fold change ≤ -3 and ≥ 3). For those gene transcripts that were significantly 
different (unadjusted p-value ≤ 0.05), a post-hoc Tukey HSD test was performed to determine 
which groups differed significantly at p-value ≤ 0.05 [56]. As applied in our dataset, the Tukey 
HSD is conservative as the sample sizes differ [57]. 
Clustering: Hierarchical clustering was performed following ANOVA, using probe-sets 
filtered as noted above. The values of gene expression were median centered and normalized to a 
standard deviation of 1. Using the results, we generated a heat map to demonstrate sample 
relationships in terms of gene expression. K-means clustering was also performed following 
ANOVA to cluster the genes that have similar expression patterns. The two-level approach was 
applied with analysis of cHBL and BFH groups. K-means clustering is a partition clustering, and 
clusters the data into groups preset by the researcher. Using the set of observed survival times, we 
utilized the Kaplan-Meier survival curve, which shows the survival time in a “step function”. 
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Gene Ontology Analysis: Data was uploaded to QIAGEN’s Ingenuity Pathway Analysis 
(IPA, QIAGEN Redwood City, http://www.qiagen.com/ingenuity) for biological annotation. All 
analyses were conducted with IPA defined defaults. The p-value was calculated using a right-tailed 
Fisher Exact Test that, for a given annotation process, is calculated by considering both the number 
of focus genes within that process and the total number of genes that are associated with that 
process in the reference set [62]. Overall, p-values ≤0.05 indicate a statistically significant, non-
random association. P-values listed for IPA analysis are uncorrected except where noted. We used 
uncorrected p-values as starting points for further downstream analysis because Fisher’s exact test 
can be overly conservative with small sample sizes as we have here [63, 64]. For specific 
hypothesis testing, we used the Benjamini-Hochberg method of correction [62, 65]. 
Methylation-specific PCR for Validation: To validate the DNA methylation sequencing 
results, we used a Methylation-specific PCR (MSP). MSP was designed based on publicly 
available databases [66-69]. The technique is summarized as follows: (1) Two restriction enzymes 
(RE) with cleavage sites overlapping a CpG island in the region of interest are selected. 
Importantly, one RE is methylation sensitive while the other (an isoschizomer) is not. (2) After 
digestion with the REs, a PCR using specific primer sets for both unmethylated and methylated 
DNA is performed. MSP is a rapid measure for assessing DNA methylation status in CpG island. 
RESULTS 
Gene Expression 
Affymetrix Array Results: After performing data clean-up and normalization using JMP 
Genomics protocol [70], we identified all differentially expressed genes with fold-change>3 and 
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p ≤ 0.001 in the cHBL (n = 71) and Benign Follicular Hyperplasia (n = 7) comparison. In total, 
we identified 1,180 differentially expressed 
transcripts, representing 464 genes.  
Gene Expression Correlated with 
Survival in Tumor Compared to Locally 
Adjacent Normal Tissue Sample: For a 
subset of the pet dogs diagnosed with cHBL 
(n = 45) survival data was available. Using 
K-mean clustering [an unsupervised 
learning algorithm; 71], we separated the 
samples into two groups based on the 
combined expression of the above 464 genes (high and low expressers). We then correlated each 
expression-based sample group 
with survival time (p ≤ 0.05) 
and generated a list of 
significant genes for each 
group. Only 6 genes overlapped 
in the lists from high and low 
expressers after selecting 
significant transcripts (fold-
change > 3 and p < 0.001) in subset of dogs and correlating with survival time (Table 2).  
 
 
Table 2: Genes Significantly Correlated with 
Survival in High-Grade Canine Lymphomas. The 
gene names and symbols we identified are presented 
with the range of p-values, the total number of 
transcript represented by the gene, and the number of 
significant transcripts.  
Table 3: Differentially Methylated DNA regions in DLBCL & 
Locally Adjacent Normal Tissue. We report the overall DNA methylated 
regions in 5 different features specifically selected using MeDIP. Presented are 
the total number of significant and percentage of significant regions, percentage 
of hypomethylated regions and percentage of hypermethylated regions in 
DLBCL. 
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DNA Methylation 
Differentially Methylated Regions in Tumor Compared to Locally Adjacent Normal Tissue 
Sample: 
In total, we identified 4,891 differentially methylated genes representing 3 major elements: 
Promoter (DMRs = 1,190), First Exon (DMRs = 633), and All Exons (DMRs = 3,060; Table 3). 
We focused the remaining analysis on the first exon since DNA methylation of this element is 
most closely associated with gene transcription. Using only the 633 DMRs, we identified the top 
five canonical pathways that were overly represented by number of genes from that pathway in 
our significant DMRs. These included: G-protein coupled receptor signaling, cAMP-mediated 
signaling, hepatic fibrosis, glucocorticoid receptor signaling, and communication between innate 
and adaptive immune cells.  
Ingenuity Pathway Analysis 
Statistically significant canonical pathways were analyzed using the Ingenuity Pathway 
Analysis (IPA) for the differentially methylated regions of the first exon. After selecting the 
significant transcripts (fold 
change > 2 and p < 0.001) the 
top five most significant genes 
were determined in both 
DLBCL and locally adjacent 
normal tissues (LANT). In this 
comparison, the five significant 
genes in the LANT group 
signified as having lowest fold Table 4: Top 5 Genes with the Largest and Smallest Fold-Change 
in DLBCL Compared to Normal Tissue. 
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change in DLBCL. Table 4 shows the top five significant genes for LANT and DLBCL 
comparison.  
 In addition, the top five canonical pathways in both LANTs and DLBCL were determined 
using the same significant transcripts (fold change > 2 and p < 0.001) for each group. In LANTs, 
the top five canonical pathways were glucocorticoid receptor signaling, neuroinflammation 
signaling pathway, hepatic fibrosis/hepatic stellate cell activation, cAMP-mediated signaling, and 
corticotropin releasing hormone signaling. In DLBCL, the top five canonical pathways included 
G-protein coupled receptor signaling, hepatic fibrosis/hepatic stellate cell activation, cAMP-
mediated signaling, glutamate dependent acid resistance, and embryonic stem cell differentiation 
into cardiac lineages. Between the two groups, cAMP-mediated signaling and hepatic 
fibrosis/hepatic stellate cell activation were the pathways seen in both groups.  
Comparison of Expression and DNA Methylation Results 
We found that CDH1 was more hypermethylated compared to the control at the first 
exon. Hypermethylation suggests decreased expression, and this was confirmed in our 
expression data. Through Treehouse, 
the publicly available pediatric 
expression dataset, expression values in 
DLBCL were analyzed. We found that 
decreased expression of CDH1 was a 
predictor of death by the median 
survival. These findings were validated 
in 91 pediatric tumors with survival 
data. Additionally, decreased CDH1 Figure 1: Expression Values for Pediatric DLBCL of CDH1. 
Those who expressed lower levels of CDH1 were more likely to 
die from their disease than higher expressers. 
Death Survival 
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expression is associated with poor survival in multiple types of cancers. Overall, the expression 
of this gene was significantly associated with survival in pediatric lymphoma (p = 0.013; see 
Figure 1).  
DISCUSSION 
All of the 6 prognostic genes identified through differential gene expression, have 
biological roles that are significant for cancer development. CDH1 is a known tumor suppressor 
gene, where knockdown or silencing of this gene can lead to increase in cancer proliferation and 
invasion [72]. ITGA6 is known to promote tumorigenesis, causing alternative splicing in transcript 
variants [73]. KCNJ8 regulate integral membrane proteins and influences potassium channel which 
are responsible for variety of physiological responses [74]. LAMB1 controls cell adhesion, 
differentiation, migration, signaling, and cancer metastasis [75]. PEG3 is associated with cell 
proliferation and apoptosis as well as potential for suppressing tumor growth [76]. Lastly, RAMP2 
is a gene that suppresses metastasis and maintain vascular integrity [77].  
Utilizing IPA, the top five significant genes in LANTs and DLBCL of first exon were 
determined. In LANTs, the top five significant genes were MIR449B, OCLN, MIR8880, MIR506, 
and TNNT2. The MIR genes are microRNAs, which are involved in post-transcriptional regulation 
of gene expression by affecting the translation of mRNAs. MicroRNAs can recognize the target 
mRNAs and cause translational inhibition or destabilization of that mRNA. The OCLN gene 
encodes an integral membrane protein, affecting platelet function tests and is highly expressed in 
the thyroid gland. TNNT2 encodes the protein in tropomyosin-binding subunit, which is highly 
expressed in left ventricle of the heart. It influences the regulation of cholesterol (HDL), 
neurofibrillary tangles, and troponin T.  
In addition, the most common canonical pathways seen in this group include glucocorticoid 
receptor signaling, neuroinflammation signaling pathway, hepatic fibrosis/hepatic stellate cell 
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activation, cAMP-mediated signaling, and corticotropin releasing hormone signaling. 
Glucocorticoid receptor signaling significantly affects anti-inflammatory, immunosuppressive, 
and inflammatory-disease modulation. Glucocorticoids, like other corticosteroids, have been used 
for treatment of cancers for their anti-proliferative and antiangiogenic properties [78]. As with 
glucocorticoids, neuroinflammation signaling pathway is involved with inflammation. It is known 
that cancer inflammation can promote or exacerbate cancer development [79]. Hepatic stellate cell 
activation is also a pro-inflammatory state, where prolonged hepatic injury can cause the 
accumulation of activated hepatic stellate cells. This can lead to irreversible state of liver cirrhosis. 
Hepatic stellate cell clearance has also been associated with apoptosis [80]. The c-AMP-mediated 
signaling regulates cell growth, cell differentiation, gene transcription, and protein expression. As 
a second messenger pathway, it is associated with multiple diseases such as inflammation, cancer, 
and myocardial atrophy [81]. Lastly, corticotropin releasing hormone signaling pathway affects 
the hypothalamic-pituitary-adrenal (HPA) axis and is a principle pathway for stress response. 
Corticotropin releasing hormone is also known to employ the cAMP cascade, which has an effect 
on cancer development [82]. Some of the diseases and disorders that were most commonly affected 
by the LANTs group were metabolic disease, endocrine system disorders, GI disease, organismal 
injury and abnormalities, and connective tissue disorders. 
Within the DLBCL group, the top five significant genes were ARX, PPP1R2, HPGD, 
MAOB, and SRP68. ARX is a highly expressed gene in the ovary and is a lipoprotein affecting gene 
that is expressed during development. PPP1R2 is one of the main eukaryotic serine/threonine 
phosphates that is highly expressed in the testis. HPGD encodes enzyme that is responsible for 
metabolism of prostaglandins and is highly expressed in the bladder. It influences the platelet 
function tests, venous thromboembolism, insulin like growth factor I, blood pressure, and body fat 
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distribution. MAOB encodes the protein that belongs to flavin monoamine oxidase family. It is 
highly expressed in the ovary and affects aorta, smoking, and bipolar disorder. Lastly, SRP68 is a 
gene that encodes a subunit of signal recognition particle (SRP). It is highly expressed in cells 
especially the transformed fibroblasts.   
The top canonical pathways seen in this set of genes include the G-protein coupled receptor 
signaling, hepatic fibrosis/hepatic stellate cell activation, cAMP-mediated signaling, glutamate 
dependent acid resistance, and embryonic stem cell differentiation into cardiac lineages. G-protein 
coupled receptor signaling regulate the cell cycle progression. Recent evidence shows that G-
protein coupled receptors have effect on cancer development, including vascular remolding, 
invasion, and migration [83]. The glutamate dependent acid resistance is utilized by neutralophilic 
bacteria to combat environmental situations with low pH. These bacteria that affect humans, utilize 
this pathway to cope with acid stress, or to protect cells from acidic environment such as the 
intestines [84]. Lastly, the embryonic stem cells have the potential to be differentiated into cardiac 
progenitor cells, to utilize as a cell-based therapy for heart disease [85]. The most common diseases 
associated with the DLBCL group include cancer, organismal injury and abnormalities, 
neurological disease, skeletal and muscular disorders, and hereditary disorders. Between the 
LANTs and DLBCL, the only overlapping disorder was organismal injury and abnormalities. 
CONCLUSION 
This study is one of the first to provide an alternative model for aggressive lymphomas in 
children. Pet dog models are valuable for higher understanding of the genetic basis of pediatric 
high-grade lymphomas. Through studying of differential gene expression and differential DNA 
methylation, CDH1 was identified as the overlapping gene. In both canine and pediatric high-grade 
lymphomas, CDH1 is indicative of decreased survival. More research to understand the genetic 
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mechanism of CDH1 is still necessary to fully understand its biomarker relevance for future 
clinical application. 
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